{
    "brief_title": "FUSCC Refractory TNBC Umbrella (FUTURE)",
    "phase": "Phase 1; Phase 2",
    "drugs": "['Pyrotinib with Capecitabine', 'AR inhibitor combined with everolimus(B1) or CDK4/6 inhibitor(B2),or EZH2 inhibitor (B4)', 'anti PD-1 with nab-paclitaxel', 'PARP inhibitor included therapy', 'BLIS with anti-VEGFR included therapy', 'MES with anti-VEGFR included therapy', 'mTOR inhibitor with nab-paclitaxel']",
    "drugs_list": [
        "Pyrotinib with Capecitabine",
        "AR inhibitor combined with everolimus(B1) or CDK4/6 inhibitor(B2),or EZH2 inhibitor (B4)",
        "anti PD-1 with nab-paclitaxel",
        "PARP inhibitor included therapy",
        "BLIS with anti-VEGFR included therapy",
        "MES with anti-VEGFR included therapy",
        "mTOR inhibitor with nab-paclitaxel"
    ],
    "diseases": "['Triple-negative Breast Cancer']",
    "diseases_list": [
        "Triple-negative Breast Cancer"
    ],
    "enrollment": "140.0",
    "inclusion_criteria": "inclusion criteria: \n\n ECOG Performance Status of 0, 1, or 2 \n\n Metastatic or locally advanced, histologically documented TNBC (absence of HER2, ER, and PR expression) \n\n Radiologic/objective evidence of recurrence or disease progression after available standard chemotherapy regimens(anthracyclines,taxanes, platinums, vinorelbine,capacitabine, and gemcitabine included) for metastatic breast cancer(MBC) \n\n Availability of a representative tumor specimen that is suitable for rebiopsy, IHC staining and gene sequencing \n\n Adequate hematologic and end-organ function, laboratory test results, obtained within 14 days prior to initiation of study treatment. \n\n For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures as outlined for each specific treatment arm \n\n Measurable disease according to Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1) \n\n have the cognitive ability to understand the protocol and be willing to participate and to be followed up. \n\n ",
    "exclusion_criteria": ": \n\n Symptomatic, untreated, or actively progressing CNS metastases \n\n Active or history of autoimmune disease or immune deficiency \n\n Significant cardiovascular disease \n\n History of malignancy other than breast cancer within 5 years prior to screening, with the exception of those with a negligible risk of metastasis or death \n\n Treatment with chemotherapy, radiotherapy,immunotherapy or surgery (outpatient clinic surgery excluded)within3 weeks prior to initiation of study treatment. \n\n Pregnancy or breastfeeding, or intention of becoming pregnant during the study",
    "brief_summary": "This is a Phase Ib/II, open-label, multi-center umbrella study evaluating the efficacy and safety of multiple targeted treatment in patients with refractory metastatic TNBC.The specific grouping of patients' depends on FUSCC 500+ gene panel testing and IHC subtype staining.",
    "NCT_ID": "NCT03805399"
}